20th Dec 2016 07:19
LONDON (Alliance News) - Drugmaker GlaxoSmithKline PLC on Tuesday said its ViiV Healthcare Ltd joint venture has received positive results from the first phase 3 studies on its two-drug HIV treatment.
ViiV is Glaxo's HIV joint venture with the US's Pfizer Inc and Japan's Shionogi & Co Ltd. Glaxo has a 76.5% stake in ViiV, whilst Pfizer holds 13.5% and Shionogi 10%.
Glaxo said both of the phase 3 studies evaluating the safety and efficacy of switching HIV sufferers from a three or four-drug regimen to a two-drug treatment programme have met their primary endpoint of non-inferiority at week 48 of the programme.
"These are important results for the HIV scientific community and represent an important milestone in our understanding of how HIV can be treated. The results support our strategy of investigating two-drug regimens as innovative treatment options for people living with HIV and we are planning regulatory submissions for this two-drug regimen as a single tablet in 2017," said Dominique Limet, the chief executive of ViiV.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline